Tobacco Dependence Treatment From Neurobiology through Public Policy
|
|
- Sibyl Hill
- 5 years ago
- Views:
Transcription
1 Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National Institutes of Health National Cancer Institute P50CA R21CA P Mary Ellen Wewers, PhD, MPH, RN 1
2 Objectives: To describe prevalence of tobacco use among patients with mental illness. To characterize a new theory about the neurobiology of nicotine addiction. To describe evidence-based clinical interventions for tobacco dependence treatment for patients/clients with mental illness. To discuss policy level tobacco control interventions for implementation in health care settings and communities. Background information: Smoking prevalence among those with mental illness Mary Ellen Wewers, PhD, MPH, RN 2
3 Adult Smoking Prevalence CDC Mental Illness* Male 40 Mental Illness* Female % U.S *Diagnosed mental, behavioral or emotional disorder Excludes developmental or substance abuse disorder Smoking & Mental Illness: By poverty level CDC % At or above Below Mary Ellen Wewers, PhD, MPH, RN 3
4 Smoking and Mental Illness: By age CDC % Smoking and Mental Illness: By education CDC % Less than HS HS grad Some college College graduate Mary Ellen Wewers, PhD, MPH, RN 4
5 Smoking and Mental Illness: By race/ethnicity CDC 2013 % Smoking and Mental Illness: By region CDC % Midwest South Northeast West 10 0 Mary Ellen Wewers, PhD, MPH, RN 5
6 Smoking prevalence by psychiatric diagnosis Lasser et al % Bipolar Disorder Gen Anxiety Disorder Schizophrenia Major Depression 0 None History Active Active Smoking and schizophrenia Meta-analysis of 42 studies on tobacco smoking among schizophrenia patients found an average smoking prevalence of 62% (range 14-88%) Citation bias Studies reporting higher prevalence were more commonly cited in the research literature Trend was also apparent on the Internet Chapman et al Mary Ellen Wewers, PhD, MPH, RN 6
7 Smoking and Mental Illness: Over time NHSDA ; NSDUH % Serious psychological distress No serious psychological distress Neurobiology of Nicotine Addiction Mary Ellen Wewers, PhD, MPH, RN 7
8 Neurobiology of Nicotine Addiction Neurochemical and related effects of nicotine Nicotine Dopamine Norepinephrine Acetylcholine Glutamate Serotonin β-endorphin GABA Pleasure & Appetite suppression Arousal & Appetite suppression Arousal & Cognitive enhancement Learning & Memory enhancement Reduced anxiety & Reduced tension Mood modulation & Appetite suppression Benowitz 2008 Mary Ellen Wewers, PhD, MPH, RN 8
9 Stages of Addiction Volkow et al Stage Binge & intoxication Shifting drivers resulting from neuroadaptation Feeling euphoric Feeling good Escaping dysphoria Withdrawal & negative affect Feeling reduced energy Feeling reduced excitement Feeling depressed, anxious, restless Preoccupation & anticipation Looking forward Desiring drug Obsessing and planning to get drug Transition from experimentation to addiction: a function of progressive neuroadaptation Voluntary Action Abstinence Constrained use Behavioral Changes Sometimes: taking when not intended having trouble stopping taking more than intended Impulsive action Relapse Compulsive use Mary Ellen Wewers, PhD, MPH, RN 9
10 Neurobiology of Addiction Volkow et al Addiction is an acquired brain disease Onset starts in adolescence Developing brain is sensitive to drug-induced neuroplasticity Nicotine exposure leads to changes in synaptic signaling between neurons and reward regions of brain Prevention is key during adolescence Adult brain requires behavioral and pharmacological treatment Mary Ellen Wewers, PhD, MPH, RN 10
11 Clinical Interventions for Tobacco Dependence Treatment The Health Impact Pyramid Thomas Friedan, 2010 Increasing Population Impact Increasing Individual Effort Needed Counseling and Education Clinical Interventions Tobacco dependence treatment Long-lasting Protective Interventions Tobacco 21, Banning ads to youth Changing the Context to Make Healthy Default Decisions Smoke-free laws, Tobacco tax Socioeconomic Factors Poverty, education, employment Mary Ellen Wewers, PhD, MPH, RN 11
12 Just as Ready to Quit Smoking Acton 2001;Prochaska 2004,2006; Nahvi 2006 % Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service All patients should be Screened for tobacco use Advised to quit Offered treatment All patients should be offered pharmacological treatment, unless contraindicated There is a dose-response relationship between intensity of treatment and abstinence Endorsed by APNA Mary Ellen Wewers, PhD, MPH, RN 12
13 Available First-line Pharmacotherapies US PHS 2008 Long term ( 6 month) quit rates % Mary Ellen Wewers, PhD, MPH, RN 13
14 Varenicline in Smokers with Depression Anthenelli et al % abstinent 525 adults with stably treated or past depression Significant treatment effects at all time points (p.001) Non-significant difference in suicidal ideation Most frequent AE: Nausea (27%) 2 deaths in Varenicline group (during non-tx phase) Varenicline in Smokers with Schizophrenia Williams et al % abstinent 127 stable outpatient adults Significant treatment effects at both time points (p.001) No evidence of symptom exacerbation Varenicline was well tolerated Mary Ellen Wewers, PhD, MPH, RN 14
15 Varenicline for Relapse Prevention: Smokers with Schizophrenia and Bipolar Disorder Evins et al % abstinent 87 participants who were continuously abstinent (CA) at week 12 Randomized to CBT and varenicline or placebo from weeks Followed to week 76 Significant treatment effects at all time points (p.001) Meta-analyses for bupropion among persons with schizophrenia Tsoi et al Banham et al Six randomized clinical trials 260 participants End of treatment abstinence OR = 2.57 (95% CI ) 6 month abstinence OR = 2.78 (95% CI ) Conclusion: Bupropion was found to be well tolerated in patients with schizophrenia who are stabilized on an adequate antipsychotic regime Mary Ellen Wewers, PhD, MPH, RN 15
16 FDA Boxed Warning For patients with serious neuropsychiatric symptoms Patients should be advised to stop taking varenicline or bupropion and to contact a health-care provider immediately if they experience agitation, depressed mood, and any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior Cochrane Network Meta-Analysis: Serious Adverse Events (SAE) Cahill et al Bupropion studies (n=7859) Event rate for any SAE 2.5% drug vs. 2.2% placebo Neuropsychiatric event rate 0.8% drug vs. 0.9% placebo No excess of neuropsychiatric events 14 Varenicline trials (n=6333) Event rate for any SAE 2.1% drug vs. 2.0% placebo Neuropsychiatric event rate 0.15% drug vs. 0.21% placebo No excess of neuropsychiatric events Mary Ellen Wewers, PhD, MPH, RN 16
17 Meta-analysis: Varenicline & Neuropsychiatric AE Thomas et al Trials (n=10,761 participants) Relative to placebo No increased risk of Suicide or attempted suicide (OR=1.67, ) Suicidal ideation (OR=0.58, ) Depression (OR=0.96, ) Aggression (OR=0.91, ) Increased risk of Sleep disorders (OR=1.63, ) Insomnia (OR=1.56, ) Abnormal dreams (OR=2.39, ) Fatigue (OR=1.28, ) Decreased risk of anxiety (OR=0.75, ) Behavioral Counseling Cognitive behavioral therapy (CBT) in combination with pharmacotherapy significantly improves treatment outcomes Individual counseling = group counseling Proactive telephone counseling is efficacious USPHS Clinical Practice Guideline 2008 Quit line counseling not tailored to those with mental illness 25% of California Quitline callers met criteria for current major depression Hebert et al Mary Ellen Wewers, PhD, MPH, RN 17
18 Specialized Telephone Counseling for Mental Health Clinic Patients Rogers et al Percent abstinent at 6 mo * OR=1.62, Conducted in VA Health System in NE U.S. 577 Mental Health clinic patients referred for treatment by HCP Specialized telephone counseling regarding mental health issues vs. referral to state quit line Mailed medications to both groups Policy Approaches Mary Ellen Wewers, PhD, MPH, RN 18
19 The Health Impact Pyramid Thomas Friedan, 2010 Increasing Population Impact Increasing Individual Effort Needed Counseling and Education Clinical Interventions Tobacco dependence treatment Long-lasting Protective Interventions Tobacco 21, Banning ads to youth Changing the Context to Make Healthy Default Decisions Smoke-free laws, Tobacco tax Socioeconomic Factors Poverty, education, employment Tobacco Control Best Practices Comprehensive smoke-free laws High tobacco taxes/prices Funding for tobacco control programming Counter-marketing Treatment for nicotine addiction Surveillance Support for local coalitions Mary Ellen Wewers, PhD, MPH, RN 19
20 Smoke Free Environments NASMHPD % Impact of Cigarette Price Increases on U.S. Cigarette Sales TCLC/CPHSS 2014 Mary Ellen Wewers, PhD, MPH, RN 20
21 Smokers with a mental health diagnosis are price sensitive Ong et al For every 10% increase in the price of cigarettes Treatment for Nicotine Addiction Offer tobacco dependence treatment 25% of mental health centers 42% of substance abuse treatment centers SAMHSA 2010, 2013 Affordable Care Act Mental Health Parity and Addiction Equity Act Mary Ellen Wewers, PhD, MPH, RN 21
22 Medicaid Coverage for Tobacco Dependence Treatments in Massachusetts and Associated Decreases in Smoking Behavioral Counseling + Pharmacotherapy Land et al The Health Impact Pyramid Thomas Friedan, 2010 Increasing Population Impact Increasing Individual Effort Needed Counseling and Education Clinical Interventions Tobacco dependence treatment Long-lasting Protective Interventions Tobacco 21, Banning ads to youth Changing the Context to Make Healthy Default Decisions Smoke-free laws, Tobacco tax Socioeconomic Factors Poverty, education, employment Mary Ellen Wewers, PhD, MPH, RN 22
23 Adolescents and Prevention What s next Regulating tobacco product ingredients Flat minimum price of $10.50 per pack New York City Tobacco 21 Institute of Medicine Recommendations ~ 80 municipalities and State of Hawaii Mary Ellen Wewers, PhD, MPH, RN 23
24 Conclusions Prevalence of smoking is significantly higher among those with a mental illness Smokers with a mental health diagnosis want to quit smoking Tobacco control involves a comprehensive, multilevel approach Clinical interventions are effective Policy level approaches enhance individual level treatment Mary Ellen Wewers, PhD, MPH, RN 24
Strategies for Integrating Smoking Cessation & Wellness into Psychiatric & Substance Abuse Treatment Settings
Strategies for Integrating Smoking Cessation & Wellness into Psychiatric & Substance Abuse Treatment Settings Antoine Douaihy, MD Associate Professor of Psychiatry University of Pittsburgh School of Medicine
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationVarenicline Update. Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, Norway
Varenicline Update Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, orway October 23, 2015 Disclosures related to smoking cessation: Pfizer, Mceil, ovartis Binding
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationTobacco Treatment during Addictions Treatment or Recovery: A Review of the Literature
Tobacco Treatment during Addictions Treatment or Recovery: A Review of the Literature Judith J. Prochaska, PhD, MPH University of California, San Francisco Research supported by NIDA #P50-DA09253 and #K23-DA018691,
More informationTobacco Use Dependence and Approaches to Treatment
University of Kentucky UKnowledge Nursing Presentations College of Nursing 11-2011 Tobacco Use Dependence and Approaches to Treatment Audrey Darville University of Kentucky, audrey.darville@uky.edu Chizimuzo
More informationSmoking Cessation: Treating Tobacco Dependence
Smoking Cessation: Treating Tobacco Dependence Pat Folan, RN Center for Tobacco Control Pulmonary Medicine NS-LIJ Health System NYS DOH Tobacco Control Program Treating Tobacco Dependence Center for Tobacco
More informationSetting the Stage: Tobacco s Impact on Smokers, Employers, and Florida
Setting the Stage: Tobacco s Impact on Smokers, Employers, and Florida Thomas H. Brandon, Ph.D. H. Lee Moffitt Cancer Center & Research Institute Florida Tobacco Cessation Summit October 14, 2010 Moffitt
More informationDrug Use Evaluation: Smoking Cessation
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501 Phone 503-947-5220 Fax 503-494-1082 Drug Use Evaluation: Smoking Cessation Tobacco cessation
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationTobacco & Nicotine: Addiction and Treatment
Tobacco & Nicotine: Addiction and Treatment Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University of Washington, School
More informationNeurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP
Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the
More informationBrief Intervention for Smoking Cessation. National Training Programme
Brief Intervention for Smoking Cessation National Training Programme Introduction Monitor tobacco use and prevention policies Protect people from tobacco smoke Offer help to quit tobacco use Warn about
More informationAddressing Tobacco Use in Iowa
Addressing Tobacco Use in Iowa A BRIEF TOBACCO INTERVENTION FOR HEALTHCARE PROVIDERS Lorene Mein Beth Turner Alyssa Reichelt DNP, ARNP, FNP-BC MA, CHES MA Mercy Clinics American Lung Association American
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationSmoking Cessation: Where Are We Now? Nancy Rigotti, MD
Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for
More informationKeywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )
Review Article and Clinical Experience: ENICLINE (CHAMPIX ) : A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist) Askandar Tjokroprawiro Diabetes
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationSmoking Cessation Strategies in 2017
Smoking Cessation Strategies in 2017 Robert Schilz DO, PhD, FCCP Division of Pulmonary, Critical Care and Sleep Medicine Director of Lug Transplantation University Hospitals of Cleveland Case Western University
More informationManagement of Tobacco Dependence. Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur
Management of Tobacco Dependence Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur Difficult to identify any other condition that presents such a mix of lethality, prevalence,
More informationSmoking cessation and reduction in people with chronic mental illness
Link to this article online for CPD/CME credits Smoking cessation and reduction in people with chronic mental illness Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationUpdates in the Treatment of Tobacco Use Disorder
Updates in the Treatment of Tobacco Use Disorder Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures Grant Support from Pfizer
More informationTreating Tobacco Use:
Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary
More informationsubstance use and mental disorders: one, the other, or both?
substance use and mental disorders: one, the other, or both? Stephen Strobbe, PhD, RN, PMHCNS-BC, CARN-AP Dawn Farm Education Series St. Joe s Education Center, Ypsilanti, MI Tuesday, January 27, 2015
More informationSmoking Cessation. MariBeth Kuntz, PA-C Duke Center for Smoking Cessation
Smoking Cessation MariBeth Kuntz, PA-C Duke Center for Smoking Cessation Objectives Tobacco use at population level Tobacco use and control around the world What works for managing tobacco use Common myths
More informationEvidence-based Practice
Evidence-based Practice Michael V. Burke, EdD Assistant Professor of Medicine Treatment Program Coordinator Mayo Clinic Nicotine Dependence Center May, 2013 Learning objectives At the end of this presentation
More informationSupporting smokers with mental health problems
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) Supporting smokers with mental health problems Ann McNeill, Professor of Tobacco Addiction Dr Debbie
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationPrimary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco
Primary Care Smoking Cessation Dr John McMenamin GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco Target or Tickbox? The Tobacco health target:
More informationIndividuals with Psychiatric and Substance Use Disorders Comprise an Important Segment of Smokers & Consume Nearly 1 in 2 Cigarettes Sold
Introducing the EAGLES Trial: Its Purpose, Findings & Implications Robert M. Anthenelli, M.D. Professor and Executive Vice Chair Director, Pacific Treatment and Research Center Department of Psychiatry
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationPharmacologic Therapy for Tobacco Use & Dependence
Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications
More informationProject ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D.
Project ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D. High Levels Of Tobacco Use Almost twice as likely to smoke as people without disorders (36.1%
More informationA systems approach to treating tobacco use and dependence
A systems approach to treating tobacco use and dependence Ann Wendland, MSL Policy Analyst & Cessation Programs Manager NYSDOH Bureau of Tobacco Control ann.wendland@health.ny.gov A systems approach to
More informationProgress toward quitting. The cessation environment in New York
Progress toward quitting The cessation environment in New York TCP Vision and Mission Vision: All New Yorkers live in a tobacco free society. Mission: Reduce morbidity and mortality and alleviate social
More informationButt in: Support for patients who smoke
Butt in: Support for patients who smoke Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree May 2018 Disclosures In relation to this presentation, I declare the
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More information6B / Boswell, Grant and Slutske Day 2 August 14, 2008
Pharmacological Treatment of Pathological Gambling Jon E. Grant, JD, MD, MPH Associate Professor University of Minnesota School of Medicine Minneapolis, MN Disclosure Information I have the following financial
More informationHIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA
HIV and Aging Making Tobacco Cessation a Priority in HIV/AIDS Services June 27, 2008 Amanda Brown, MPH Ruth Tripp, MPH, RN Objectives To explore existing knowledge of the HIV and smoking connection. To
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationTobacco Use in Populations with Mental Illness and/or Substance Use Disorders
Tobacco Use in Populations with Mental Illness and/or Substance Use Disorders Pat McKone, Regional Senior Director American Lung Association of the Upper Midwest Tobacco Control Programs and Policy Adult
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More informationSmoking Still Kills! (Figs for England)
Smoking Cessation Gay Sutherland (Clinical Psychologist) Visiting Researcher - Tobacco Research Unit Inst. of Psychiatry, Psychology & Neuroscience King s College London Smoking Still Kills! (Figs for
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 55 Lave Ave No, Worcester, MA 01655 www.umassmed.edu/tobacco 2016 Basic Skills for Working with Smokers 1 Table of
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationREACH, ENGAGE, HELP:
REACH, ENGAGE, HELP: Smokers with Mental Illness Judith J. Prochaska, PhD, MPH UCSF Department of Psychiatry The Death of a 56-Year-Old Man With Serious Mental Illness A 56-year-old, gay-identified Caucasian
More informationTobacco Cessation, E- Cigarettes and Hookahs
Objectives Tobacco Cessation, E- Cigarettes and Hookahs Discuss evidence-based tobacco cessation interventions including pharmacologic options. Review e-cigarette and hookah facts and safety considerations.
More informationTobacco Use and Cessation in Psychiatric Patients
Tobacco Use and Cessation in Psychiatric Patients John Spangler, MD, MPH Professor of Family Medicine Wake Forest School of Medicine NCPA, October 2015 Disclosure I have no relevant financial relationship
More informationTobacco Research at NIDA: Neuroscience, Treatment and Regulatory-related studies
% of Basal Release Dopamine (nm) Wilson M. Compton, MD, MPE Deputy Director, National Institute on Drug Abuse Tobacco Research at NIDA: Neuroscience, Treatment and Regulatory-related studies Themes for
More informationButt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency
Butt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency Emma Dean Acting Population Health and Health Promotion Coordinator Alfred Health Wednesday 30 th May 2018 2 Disclosures
More informationSmoking Cessation A Clinicians Perspective. Jeff Wilson, MD
Smoking Cessation A Clinicians Perspective Jeff Wilson, MD Overview Tobacco control what we have accomplished and the road ahead Role of the health care professional Using pharmacotherapy Electronic cigarettes
More informationDepression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital
Depression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital 2010-2012 Ülle Ani 1, Kersti Pärna 2, Inge Ringmets 2, Tiina Mändla 3. 1 Tartu
More informationUnderstanding the Impact of Cigarette Smoking Using Brain Imaging
Understanding the Impact of Cigarette Smoking Using Brain Imaging Angelica Morales, PhD Postdoctoral Fellow Developmental Brain Imaging Lab Oregon Health & Science University No Financial Disclosures The
More informationNICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1
NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION 3 rd of 3 Prep for Session 1 CHEMISTRY of NICOTINE Pyridine ring N H N CH 3 Pyrrolidine ring Nicotiana tabacum Natural liquid alkaloid Colorless, volatile
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 368 Plantation Street, Worcester, MA 01605 www.umassmed.edu/tobacco 2018 Basic Skills for Working with Smokers 1 Table
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationNeurobiology of Addiction. Jon E. Grant, JD, MD, MPH Professor University of Chicago
Neurobiology of Addiction Jon E. Grant, JD, MD, MPH Professor University of Chicago Disclosure Information I have the following financial relationships to disclose: My research is supported by NIDA, AFSP,
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationSave a Life in 3 Minutes
Save a Life in 3 Minutes Tobacco Cessation for Dental Hygiene Care Produced by Margaret J. Fehrenbach, RDH, MS 1 Not since the polio vaccine has this nation had a better opportunity to make a significant
More informationTobacco Control Highlights Wisconsin
Tobacco Control Highlights Wisconsin Health Consequences and Costs Smoking - Attributable Mortality (SAM), 2000-2004 Smoking - Attributable Productivity Losses, 2000-2004 Smoking - Attributable Expenditures
More informationSlide 1. Slide 2. Slide 3. Reducing Tobacco Use and Nicotine Dependence in Clinical Settings. Goals for Today
Slide 1 UNIVERSITY OF HAWAI I CANCER CENTER Reducing Tobacco Use and Nicotine Dependence in Clinical Settings Pebbles Fagan, Ph.D., M.P.H. Associate Professor and Program Director Cancer Prevention and
More informationTreating Tobacco Use Disorders as an Addiction: Why clinicians should address it, and some tools to help them. PAM BENNETT KATHY GARRETT
Treating Tobacco Use Disorders as an Addiction: Why clinicians should address it, and some tools to help them. PAM BENNETT KATHY GARRETT Objectives Why Tobacco Use should be viewed as an addiction Why
More informationMonth/Year of Review: March 2014 Date of Last Review: April 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationTobacco Control Highlights Alaska
Tobacco Control Highlights Alaska Health Consequences and Costs Smoking - Attributable Mortality (SAM), 2000-2004 Smoking - Attributable Productivity Losses, 2000-2004 Smoking - Attributable Expenditures
More informationPopulation-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge
Population-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge Harlan R. Juster, Ph.D. Director, Bureau of Tobacco Control New York State Department of health November 6, 2013 Learning
More informationTraining Healthcare Providers o Deliver Brief Tobacco Interventions Strategies and Impact
Training Healthcare Providers o Deliver Brief Tobacco Interventions Strategies and Impact Thomas J Payne, PhD Professor and Director of Research Dept of Otolaryngology and Communicative Sciences Associate
More informationSmoking Cessation. May
Smoking Cessation Dear Colleague: The impact of smoking, especially for those with chronic illness, is known and staggering. Currently, there are 46.6 million smokers in the U.S., where tobacco use is
More informationSmoking cessation and weight gain
Smoking cessation and weight gain David McFadden, MD, MPH Mayo Clinic Nicotine Dependence Center 2012 MFMER slide-1 Disclosures I presented lectures for Pfizer-sponsored tobacco treatment seminars in Brazil,
More informationTobacco Cessation: Priority for Health Providers. Acknowledgements. Tobacco Cessation: Secondhand Smoke. Smoke-Free Environment & CA
Acknowledgements Smoking Cessation Leadership Center http://smokingcessationleadership.ucsf.edu/ Rx for Change http://rxforchange.ucsf.edu/ Tobacco Use and Dependence: 2008 Update http://www.surgeongeneral.gov/tobacco
More informationADHD & Addictions -What We Know
ADHD & Addictions -What We Know Dr. David Teplin, Psy.D., C.Psych. 4th CADDAC Annual Conference, Toronto October 14, 2012 1 Introduction Adult ADHD commonly co-exists with several other disorders, including
More information8/9/18. Objectives. Smoking. Disclosure Statement. The presenters have no real or potential conflicts of interest related to the presentation topic.
Disclosure Statement Multifaceted Smoking Cessation Strategies for Nurse Practitioners The presenters have no real or potential conflicts of interest related to the presentation topic. Dr. Susan Chaney,
More informationSmoking Cessation in Mental Health and Primary Care Practice
Smoking Cessation in Mental Health and Primary Care Practice 13 th Annual Statewide Integrated Care Conference Integrating Substance Use, Mental Health, and Primary Care Services: Courageous and Compassionate
More informationProject TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.
Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D. Prevalence of Smoking and Cessation During Pregnancy In 2014, 14% in women with Medicaid coverage versus 3.6% of women with
More informationSmoking Cessation Interventions In Hospital Settings: Implementing the Evidence
Smoking Cessation Interventions In Hospital Settings: Implementing the Evidence Nancy Rigotti, MD Tobacco Research & Treatment Center, General Medicine Division, Massachusetts General Hospital, Harvard
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationArticles. Funding Pfizer and GlaxoSmithKline.
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationTitle: Varenicline (Chantix) Therapy for Smoking Cessation
Title: Varenicline (Chantix) Therapy for Smoking Cessation Author: Benjamin Hersey, MS4 Date: 7 Ocber 2009 Key words: smoking cessation, varenicline Abstract: Varenicline (Chantix) can reduce the chance
More informationResearch Into Practice. Translating. Psychological. Translating Psychological Research Into Practice. Grossman Walfish. Steven Walfish.
JD, PhD, ABPP Steven Walfish, PhD Grossman Lisa Grossman, Walfish Translating Psychological Research Into Practice Ed i t o r s David H. Barlow, PhD, ABPP, Center for Anxiety and Related Disorders, Boston
More informationOur Journey Today: Winding Road
Smoking & Psychiatric Disorders: Processes, Treatment Outcomes, & Future Direction Our Journey Today: Winding Road Jonathan B. Bricker, PhD Fred Hutchinson Cancer Research Center University of Washington
More informationTobacco Use in Adolescents
Tobacco Use in Adolescents Joycelyn Lawrence, MD Leonard Miller School of Medicine at the University of Miami Department of Family Medicine 1 Overview Description: This section will introduce you to the
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationSmoking Cessation Counseling Strategies
Smoking Cessation Counseling Strategies Click to edit Master subtitle style Renato Galindo RRT-CPFT, AE-C, CTTS Objectives: Discuss factors associated with tobacco addiction Discuss tobacco cessation strategies
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationTobacco dependence: Implications for service provision
Tobacco dependence: Implications for service provision Andy McEwen, PhD University College London & National Centre for Smoking Cessation and Training (NCSCT) Tuesday 29th January 2013 Cardiff Conflict
More informationNeurobiology of Addiction and Recovery. R. Dewayne Book, M.D. Medical Director Fellowship Hall Greensboro, North Carolina
Neurobiology of Addiction and Recovery R. Dewayne Book, M.D. Medical Director Fellowship Hall Greensboro, North Carolina 1 Addiction Drug Addiction results from adaptations in specific brain neurons caused
More information